[
    [
        {
            "time": "2020-01-01",
            "original_text": "“下注中国”十大核心资产之十：迈瑞医疗（300760.SZ）",
            "features": {
                "keywords": [
                    "迈瑞医疗",
                    "核心资产",
                    "医疗"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "“下注中国”十大核心资产之十：迈瑞医疗（300760.SZ）",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-01-02",
            "original_text": "医药私募一哥，谈疫情下的医药股",
            "features": {
                "keywords": [
                    "医药私募",
                    "疫情",
                    "医药股"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药私募一哥，谈疫情下的医药股",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-01-03",
            "original_text": "低估值的海翔药业为什么难受投资者青睐？",
            "features": {
                "keywords": [
                    "海翔药业",
                    "低估值",
                    "投资者"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "低估值的海翔药业为什么难受投资者青睐？",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-01-04",
            "original_text": "我们不是基建狂魔，我们只是为了救人拼尽全力争分夺秒",
            "features": {
                "keywords": [
                    "基建",
                    "救人",
                    "努力"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "基建",
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "我们不是基建狂魔，我们只是为了救人拼尽全力争分夺秒",
                "Correlation": 4,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 3,
                "Duration": 4,
                "Entity_Density": 2,
                "Market_Scope": 6,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-01-05",
            "original_text": "好消息！湖北新增病例创近6日新低，抗新冠肺方获批，中美创新药差距大，头部公司市值差距近4倍",
            "features": {
                "keywords": [
                    "湖北",
                    "新增病例",
                    "新冠",
                    "药方获批",
                    "中美差距",
                    "市值差距"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "好消息！湖北新增病例创近6日新低，抗新冠肺方获批，中美创新药差距大，头部公司市值差距近4倍",
                "Correlation": 6,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        }
    ]
]